Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE3
Total Enrollment
94 participants
Study Classification
INTERVENTIONAL
Study Start Date
2019-08-01
Study Completion Date
2020-11-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
this study is conducted to evaluate the role of the novel triple therapy combination in reducing the mortality rate, reducing the shock time, and reversal of organ damage.
the study includes two arms, the first arm is the control which received hydrocortisone monotherapy and the second arm is the intervention arm which received the triple therapy regimen.
calculation of 28 days in-hospital mortality is the primary outcome. shock time, vasopressor doses, infection markers, and organ function tests are the secondary outcomes.
the data will be analyzed by student t-test or Mann Whitney test, Fischer exact or chi-square test for numbers, repeated measures ANOVA will be used to consider confounders and other parameters, mortality will be expressed by Kaplan Meier and ROC curve.
For Multivariate analysis of repeated quantitative outcomes, linear mixed models were used to quantify the relationship between one dependent variable (SOFA, SCr, doses of vasopressors) and many independent variables including group type and sepsis phenotype adjusted to other clinical and demographic factors.
the study includes two arms, the first arm is the control which received hydrocortisone monotherapy and the second arm is the intervention arm which received the triple therapy regimen.
calculation of 28 days in-hospital mortality is the primary outcome. shock time, vasopressor doses, infection markers, and organ function tests are the secondary outcomes.
the data will be analyzed by student t-test or Mann Whitney test, Fischer exact or chi-square test for numbers, repeated measures ANOVA will be used to consider confounders and other parameters, mortality will be expressed by Kaplan Meier and ROC curve.
For Multivariate analysis of repeated quantitative outcomes, linear mixed models were used to quantify the relationship between one dependent variable (SOFA, SCr, doses of vasopressors) and many independent variables including group type and sepsis phenotype adjusted to other clinical and demographic factors.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock
NCT03258684
Sepsis
COMPLETED
NA
Therapy With Hydrocortisone, Ascorbic Acid, Thamine in Patients With Sepsis
NCT04160676
Sepsis
COMPLETED
NA
Evaluation of Hydrocortisone, Vitamin C and Thiamine for the Treatment of Septic Shock
NCT03380507
Septic Shock
Critical Illness
TERMINATED
PHASE2/PHASE3
Vitamin C, Thiamine, Cyanocobalamine, Pyridoxine and Hydrocortisone in Sepsis
NCT04197115
Sepsis
Septic Shock
COMPLETED
PHASE3
Vitamin C, Hydrocortisone and Thiamine for Septic Shock
NCT03592693
Shock, Septic
TERMINATED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Background:
"Sepsis" is a life-threatening organ dysfunction caused by the dysregulated host response to infection. Septic Shock: Subset of sepsis with circulatory and cellular/metabolic dysfunction associated with a higher risk of mortality. Organ dysfunction can be identified by acute change in the total Sequential Organ Failure Assessment (SOFA) score of 2 points or higher consequent to the infection.
Septic shock patients can be identified by developing sepsis with persistent arterial hypotension requiring vasopressors to keep mean arterial pressure (MAP) above 65 mm Hg and having serum lactate above 2 mmol/L. In hospitals, the mortality of septic shock according to retrospective studies is around 35%-54%. Pneumonia is the most common site of infection (about 50%) of cases, followed by intra-abdominal infection and urinary tract infection.
The (1-hr Bundle) is the cornerstone of the management, it encourages clinicians to act as quickly as possible to obtain blood cultures, administer broad-spectrum antibiotics, start appropriate fluid resuscitation, measure lactate, and begin vasopressors if clinically indicated. Ideally, these interventions would all begin in the first hour from sepsis recognition but may not necessarily be completed in the first hour. However, over the last few years, there have been interesting investigational novel therapeutic approaches. One of them is the use of high dose vitamin C. A small retrospective study demonstrated a mortality benefit by using high dose vitamin C, thiamine (vitamin B1), and hydrocortisone (Triple therapy) for treatment of septic shock in the adult population.
The normal plasma vitamin C level is ≥ 23 µmol/l. A recent study found that 88% of septic shock patients have hypovitaminosis C (\<23 µmol/l), while 38% have a scurvy level (\<11 µmol/l). The acute deficiency of vitamin C in this category of patients may be caused by the increased metabolic consumption due to critical illness such (trauma, burn, septic shock, etc.).
Vitamin C has pleiotropic effects such as antioxidant (direct radical scavenger- reduction of reactive oxygen species (ROS) production-regeneration of antioxidants), anti-inflammatory, and immune-supporting, cofactor/co-substrate biosynthesis, increasing catecholamine sensitivity and protection of microcirculation. Vitamin C enteral intake is insufficient in critically ill patients due to saturable mucosal sodium-dependent vitamin C transporter 1 (SCVC1). So, supplementation of high doses of vitamin C by intravenous route can restore normal plasma concentration and reverse the stress and its sequences (reduce the incidence of organ failure, reduce vasopressor support, and may reduce the overall mortality).
Recent small controlled studies suggested the dosing range of vitamin C is from 6-16 gm/day. Also, a dose-response relationship in patients who received high doses of vitamin C was proven. Vitamin C is actively transported in tissue cells by (SCVC2), leading to achieving a high intracellular level than the plasma especially in leukocytes and neurons protecting them against ROS. While high doses of vitamin C given were not associated with any harms related to the drug, there is a theoretical concern regarding the use of high doses related to the potential risk for developing oxalate crystals in the urinary tract, For this reason, co-administration of thiamine with these high doses of vitamin C acts as a co-enzyme for the function of glyoxalate-amino transferase which catalyzes the degradation of glyoxalate to carbon dioxide instead of the oxalate. Another note is a short course of high doses vitamin C has not been found to increase the risk of renal calculi in the previous studies. Also, patients with glucose-6-phosphate dehydrogenase (G6PD) enzyme deficiency are at risk of hemolysis with high doses of vitamin C.
Thiamine has a crucial role in cellular metabolic processes. Thiamine deficiency is common in critically ill patients when becomes insufficient pyruvate not converted to acetyl coenzyme A resulting in impaired aerobic respiration and switch to anaerobic respiration leading to elevate of lactate level. Previous studies showed improvement in lactate level and in organ dysfunction with supplementation of thiamine for critically ill patients, thiamine dose is 200mg every 12 hours.
Hydrocortisone is another major component of the recommended triple therapy, the dose of hydrocortisone in septic shock is 200 mg/day, The rationale for its use is that, in septic shock, the released component of the cell membrane of gram-negative and gram-positive bacteria and endotoxins induce nitric oxide synthase which promotes the relaxation of vascular beds in addition to releasing of inflammatory cytokines such tumor necrosis factor (TNF-alpha) and interleukins (IL-1). These cytokines suppress the action of Adreno-Cortico Trophic Hormone (ACTH) on the adrenal gland and decrease the endogenous cortisol and compete with cortisol on receptor sites and diminish its effect, By supplying hydrocortisone, reversing of these mechanisms occurs which improves response to vasopressors, blocks phospholipase A2 then reduces prostacyclins and prostaglandins (vasodilators), reducing the diminished steroid action at receptor sites. Synergism appears between hydrocortisone and vitamin C based on two roles, one of them is glucocorticoid binding to glucocorticoid receptors is negatively affected by oxidizing molecules and this can be reversed by administration of high doses of vitamin C which restores the glucocorticoid receptor functions.
Also, it was found that the transcellular transportation of vitamin C via SVCT2 is impaired due to the downregulation of this transporter during septic shock, hydrocortisone has been shown increasing the expression of this transporter and then increases the cellular uptake.
Aim of the study To determine the effectiveness of triple therapy regimen (vitamin C, vitamin B1, and Hydrocortisone) in the reduction of mortality of septic shock patients.
Methodology Study subjects and designs This is an interventional, controlled, single-blind prospective parallel study to be conducted in the (ICUs) at the Air Force Specialized Hospital (AFSH), Cairo, Egypt.
Subjects will be selected according to the following inclusion and exclusion criteria:
Sample size Sample size will be calculated based on this equation
assuming the following parameters: Anticipated Incidence of mortality: GP1 (hydrocortisone arm) = 40.4%, in GP 2 (triple therapy arm) = 8.5%.
Alpha = 0.05, power = 95%, enrollment ratio = 1 So each group will consist of 44 patients (total = 88).
* By considering dropout rate = 20%, So each group will consist of 53 patients and the total sample size =106 patients.
* The first arm will take the triple therapy regimen (vitamin C, vitamin B1, and Hydrocortisone), the Second arm will take Hydrocortisone as the standard of care.
Data collection:
From each patient the following data will be collected:
* Age, gender, height and weight, and any allergies (on admission)
* Causes of ICU admission (on admission).
* Patient's past medical history (PMH) (on admission)
* SOFA score to be assessed on admission and daily (primary outcome) \[28\] and Acute Physiologic Assessment and Chronic Health Evaluation (APACHE ӏӏ) \[29\] score (on admission only).
* Hemodynamic data (blood pressure, pulse, central venous pressure (CVP), respiratory rate, O2 saturation) on admission, and daily.
* Infection markers (total leukocytic count, CRP), lactate level, serum creatinine, Aspartate Aminotransferase (AST), Alanine aminotransferase (ALT). on admission and for follow- up daily (secondary outcome).
Statistical analysis
Different statistical tests selection will be based on the type of data and the calculated outcome:
* Mortality (primary outcome) calculation will be evaluated by the chi-square test.
* Reversal of organs failure, weaning from the mechanical ventilator, and vasopressors will be evaluated using the Mann-Whitney test.
"Sepsis" is a life-threatening organ dysfunction caused by the dysregulated host response to infection. Septic Shock: Subset of sepsis with circulatory and cellular/metabolic dysfunction associated with a higher risk of mortality. Organ dysfunction can be identified by acute change in the total Sequential Organ Failure Assessment (SOFA) score of 2 points or higher consequent to the infection.
Septic shock patients can be identified by developing sepsis with persistent arterial hypotension requiring vasopressors to keep mean arterial pressure (MAP) above 65 mm Hg and having serum lactate above 2 mmol/L. In hospitals, the mortality of septic shock according to retrospective studies is around 35%-54%. Pneumonia is the most common site of infection (about 50%) of cases, followed by intra-abdominal infection and urinary tract infection.
The (1-hr Bundle) is the cornerstone of the management, it encourages clinicians to act as quickly as possible to obtain blood cultures, administer broad-spectrum antibiotics, start appropriate fluid resuscitation, measure lactate, and begin vasopressors if clinically indicated. Ideally, these interventions would all begin in the first hour from sepsis recognition but may not necessarily be completed in the first hour. However, over the last few years, there have been interesting investigational novel therapeutic approaches. One of them is the use of high dose vitamin C. A small retrospective study demonstrated a mortality benefit by using high dose vitamin C, thiamine (vitamin B1), and hydrocortisone (Triple therapy) for treatment of septic shock in the adult population.
The normal plasma vitamin C level is ≥ 23 µmol/l. A recent study found that 88% of septic shock patients have hypovitaminosis C (\<23 µmol/l), while 38% have a scurvy level (\<11 µmol/l). The acute deficiency of vitamin C in this category of patients may be caused by the increased metabolic consumption due to critical illness such (trauma, burn, septic shock, etc.).
Vitamin C has pleiotropic effects such as antioxidant (direct radical scavenger- reduction of reactive oxygen species (ROS) production-regeneration of antioxidants), anti-inflammatory, and immune-supporting, cofactor/co-substrate biosynthesis, increasing catecholamine sensitivity and protection of microcirculation. Vitamin C enteral intake is insufficient in critically ill patients due to saturable mucosal sodium-dependent vitamin C transporter 1 (SCVC1). So, supplementation of high doses of vitamin C by intravenous route can restore normal plasma concentration and reverse the stress and its sequences (reduce the incidence of organ failure, reduce vasopressor support, and may reduce the overall mortality).
Recent small controlled studies suggested the dosing range of vitamin C is from 6-16 gm/day. Also, a dose-response relationship in patients who received high doses of vitamin C was proven. Vitamin C is actively transported in tissue cells by (SCVC2), leading to achieving a high intracellular level than the plasma especially in leukocytes and neurons protecting them against ROS. While high doses of vitamin C given were not associated with any harms related to the drug, there is a theoretical concern regarding the use of high doses related to the potential risk for developing oxalate crystals in the urinary tract, For this reason, co-administration of thiamine with these high doses of vitamin C acts as a co-enzyme for the function of glyoxalate-amino transferase which catalyzes the degradation of glyoxalate to carbon dioxide instead of the oxalate. Another note is a short course of high doses vitamin C has not been found to increase the risk of renal calculi in the previous studies. Also, patients with glucose-6-phosphate dehydrogenase (G6PD) enzyme deficiency are at risk of hemolysis with high doses of vitamin C.
Thiamine has a crucial role in cellular metabolic processes. Thiamine deficiency is common in critically ill patients when becomes insufficient pyruvate not converted to acetyl coenzyme A resulting in impaired aerobic respiration and switch to anaerobic respiration leading to elevate of lactate level. Previous studies showed improvement in lactate level and in organ dysfunction with supplementation of thiamine for critically ill patients, thiamine dose is 200mg every 12 hours.
Hydrocortisone is another major component of the recommended triple therapy, the dose of hydrocortisone in septic shock is 200 mg/day, The rationale for its use is that, in septic shock, the released component of the cell membrane of gram-negative and gram-positive bacteria and endotoxins induce nitric oxide synthase which promotes the relaxation of vascular beds in addition to releasing of inflammatory cytokines such tumor necrosis factor (TNF-alpha) and interleukins (IL-1). These cytokines suppress the action of Adreno-Cortico Trophic Hormone (ACTH) on the adrenal gland and decrease the endogenous cortisol and compete with cortisol on receptor sites and diminish its effect, By supplying hydrocortisone, reversing of these mechanisms occurs which improves response to vasopressors, blocks phospholipase A2 then reduces prostacyclins and prostaglandins (vasodilators), reducing the diminished steroid action at receptor sites. Synergism appears between hydrocortisone and vitamin C based on two roles, one of them is glucocorticoid binding to glucocorticoid receptors is negatively affected by oxidizing molecules and this can be reversed by administration of high doses of vitamin C which restores the glucocorticoid receptor functions.
Also, it was found that the transcellular transportation of vitamin C via SVCT2 is impaired due to the downregulation of this transporter during septic shock, hydrocortisone has been shown increasing the expression of this transporter and then increases the cellular uptake.
Aim of the study To determine the effectiveness of triple therapy regimen (vitamin C, vitamin B1, and Hydrocortisone) in the reduction of mortality of septic shock patients.
Methodology Study subjects and designs This is an interventional, controlled, single-blind prospective parallel study to be conducted in the (ICUs) at the Air Force Specialized Hospital (AFSH), Cairo, Egypt.
Subjects will be selected according to the following inclusion and exclusion criteria:
Sample size Sample size will be calculated based on this equation
assuming the following parameters: Anticipated Incidence of mortality: GP1 (hydrocortisone arm) = 40.4%, in GP 2 (triple therapy arm) = 8.5%.
Alpha = 0.05, power = 95%, enrollment ratio = 1 So each group will consist of 44 patients (total = 88).
* By considering dropout rate = 20%, So each group will consist of 53 patients and the total sample size =106 patients.
* The first arm will take the triple therapy regimen (vitamin C, vitamin B1, and Hydrocortisone), the Second arm will take Hydrocortisone as the standard of care.
Data collection:
From each patient the following data will be collected:
* Age, gender, height and weight, and any allergies (on admission)
* Causes of ICU admission (on admission).
* Patient's past medical history (PMH) (on admission)
* SOFA score to be assessed on admission and daily (primary outcome) \[28\] and Acute Physiologic Assessment and Chronic Health Evaluation (APACHE ӏӏ) \[29\] score (on admission only).
* Hemodynamic data (blood pressure, pulse, central venous pressure (CVP), respiratory rate, O2 saturation) on admission, and daily.
* Infection markers (total leukocytic count, CRP), lactate level, serum creatinine, Aspartate Aminotransferase (AST), Alanine aminotransferase (ALT). on admission and for follow- up daily (secondary outcome).
Statistical analysis
Different statistical tests selection will be based on the type of data and the calculated outcome:
* Mortality (primary outcome) calculation will be evaluated by the chi-square test.
* Reversal of organs failure, weaning from the mechanical ventilator, and vasopressors will be evaluated using the Mann-Whitney test.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Septic Shock
Sepsis
Organ Dysfunction Syndrome Sepsis
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Hydrocortisone Monotherapy
Hydrocortisone Monotherapy
Group Type
ACTIVE_COMPARATOR
vitamin c - thiamine- hydrocortisone
Intervention Type
DRUG
Triple therapy regimen (vitamin c - thiamine- hydrocortisone)
triple therapy regimen (vitamin c - thiamine- hydrocortisone)
triple therapy regimen (vitamin c - thiamine- hydrocortisone)
Group Type
EXPERIMENTAL
vitamin c - thiamine- hydrocortisone
Intervention Type
DRUG
Triple therapy regimen (vitamin c - thiamine- hydrocortisone)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
vitamin c - thiamine- hydrocortisone
Triple therapy regimen (vitamin c - thiamine- hydrocortisone)
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Triple therapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \>18 years.
* Diagnosis of septic shock has been established (need vasopressors to maintain MAP ≥ 65, lactate ≥ 2mmol/L and SOFA score ≥2) \[25,26\].
* Diagnosis of septic shock has been established (need vasopressors to maintain MAP ≥ 65, lactate ≥ 2mmol/L and SOFA score ≥2) \[25,26\].
Exclusion Criteria
* Pregnancy and lactation.
* Refusal of attending staff or patient family.
* Contraindication to any of the components of the triple therapy regimen such as (hypersensitivity to vitamin C and Patients with G6PD deficiency).
* Patients on immunosuppressive medications and oncology patients. Do not resuscitate/do not intubate (DNR, DNI) patients
* Refusal of attending staff or patient family.
* Contraindication to any of the components of the triple therapy regimen such as (hypersensitivity to vitamin C and Patients with G6PD deficiency).
* Patients on immunosuppressive medications and oncology patients. Do not resuscitate/do not intubate (DNR, DNI) patients
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Air Force Specialized Hospital, Cairo, Egypt
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Abdelrhman Hussein
Role: PRINCIPAL_INVESTIGATOR
Air Force Specialized Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Air Force Specialized Hospital
Cairo, , Egypt
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Egypt
References
Explore related publications, articles, or registry entries linked to this study.
Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb SA, Beale RJ, Vincent JL, Moreno R; Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013 Feb;41(2):580-637. doi: 10.1097/CCM.0b013e31827e83af.
Reference Type
RESULT
Plevin R, Callcut R. Update in sepsis guidelines: what is really new? Trauma Surg Acute Care Open. 2017 Sep 7;2(1):e000088. doi: 10.1136/tsaco-2017-000088. eCollection 2017.
Reference Type
RESULT
Korosec Jagodic H, Jagodic K, Podbregar M. Long-term outcome and quality of life of patients treated in surgical intensive care: a comparison between sepsis and trauma. Crit Care. 2006;10(5):R134. doi: 10.1186/cc5047.
Reference Type
RESULT
Zahar JR, Timsit JF, Garrouste-Orgeas M, Francais A, Vesin A, Descorps-Declere A, Dubois Y, Souweine B, Haouache H, Goldgran-Toledano D, Allaouchiche B, Azoulay E, Adrie C. Outcomes in severe sepsis and patients with septic shock: pathogen species and infection sites are not associated with mortality. Crit Care Med. 2011 Aug;39(8):1886-95. doi: 10.1097/CCM.0b013e31821b827c.
Reference Type
RESULT
Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013 Aug 29;369(9):840-51. doi: 10.1056/NEJMra1208623. No abstract available.
Reference Type
RESULT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019/11
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Thiamine, Vitamin C and Hydrocortisone in the Treatment of Septic Shock
NCT03540628
COMPLETED
NA
Terlipressin Alone Versus the Standard Therapy With Catecholamines for Hepatic Patients With Septic Shock- Prospective Single Center Randomized Controlled Study.
NCT03608514
UNKNOWN
PHASE2/PHASE3
Evaluation of the Role of Hydrocortisone Either Alone or Combined With Fludrocortisone in the Outcome of Septic Shock in Adults
NCT04492280
COMPLETED
PHASE4
The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock
NCT03335124
TERMINATED
PHASE4
Vitamin C, Thiamine and Hydrocortisone for the Treatment of Septic Shock
NCT03872011
COMPLETED
PHASE3
Outcomes of Septic Shock Patients Treated With a Metabolic Resuscitation Bundle Consisting of Intravenous Hydrocortisone, Ascorbic Acid and Thiamine.
NCT03913468
COMPLETED
Vitamin C, Vitamin B1 and Steroid in Sepsis
NCT04039815
UNKNOWN
PHASE4
Effects of Glucocorticoid Combined With Vitamin C and Vitamin B1 on Microcirculation in Severe Septic Shock
NCT03821714
COMPLETED
NA
Effects of Intravenous Metabolic Recovery Agent in Elderly Septic Patients on Prognosis and Microcirculation.
NCT06723626
RECRUITING
NA
Vitamin C, Hydrocortisone and Thiamine in Patients With Septic Shock
NCT05192213
TERMINATED
PHASE3
Efficacy and Safety of Monotherapy With Noradrenaline and Terlipressin in Patients of Cirrhosis With Septic Shock Admitted to Intensive Care Unit
NCT01836224
COMPLETED
NA
Metabolic Resuscitation Using Ascorbic Acid, Thiamine, and Glucocorticoids in Sepsis.
NCT03422159
COMPLETED
PHASE2
Effect of IV Vitamin C, Thiamine, and Steroids on Mortality of Septic Shock
NCT03828929
TERMINATED
PHASE3
The Vitamin C, Hydrocortisone and Thiamine in Patients With Septic Shock Trial
NCT03333278
COMPLETED
PHASE2
Ketamine Versus Low Dose Thiopental for Induction of Anesthesia in Septic Shock
NCT03104140
COMPLETED
PHASE3
Vitamin C & Thiamine to Treat Sepsis and Septic Shock
NCT03592277
COMPLETED
PHASE2
Early Versus Conventional Cessation of Hydrocortisone in Septic Shock
NCT05818826
RECRUITING
PHASE2
Comparison of Bolus Versus Continuous Infusion of Terlipressin Cirrhotic Patients With Septic Shock.
NCT04819568
UNKNOWN
NA
Vitamin C, Steroids, and Thiamine, and Cerebral Autoregulation and Functional Outcome in Septic Shock
NCT03649633
TERMINATED
PHASE1/PHASE2
Norepinephrine / Vasopressin Combination for Resuscitation in Septic Shock
NCT04302584
COMPLETED
NA
ADjunctive coRticosteroid trEatment iN criticAlly ilL Patients With Septic Shock
NCT01448109
COMPLETED
PHASE4
Hydrocortisone for Prevention of Septic Shock
NCT00670254
COMPLETED
PHASE3
Initiation of Hydrocortisone for the Treatment of Septic Shock
NCT02580240
COMPLETED
NA
Hydrocortisone 50 mg Every 6 Hours Compared to Hydrocortisone 300 mg Per Day in Treatment of Septic Shock.
NCT02768740
COMPLETED
PHASE4
Norepinephrine Equivalent Dose of Vasopressin, Phenylephrine and Epinephrine in Septic Shock
NCT06499467
RECRUITING